APEX: a phase II randomised clinical trial evaluating the safety and preliminary efficacy of oral X-82 to treat exudative age-related macular degeneration

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

(2018) Johanna C. Bendell et al.   ONCOLOGIST

Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration

(2017) Timothy L. Jackson et al.   JAMA Ophthalmology

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis

(2017) Franziska Paech et al.   Frontiers in Pharmacology

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

(2014) Wan Ling Wong et al.   Lancet Global Health

Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration

(2012) Teresa Diago et al.   MAYO CLINIC PROCEEDINGS

Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib

(2009) Kyoichi Takahashi   ARCHIVES OF OPHTHALMOLOGY

Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib

(2008) E J Chung et al.   BRITISH JOURNAL OF OPHTHALMOLOGY